60 -12 (86) 2025 - Mun A.V., Mannanov A.M. - THE PLACE OF IMMUNOSUPPRESSIVE THERAPY WITH METHOTREXATE IN PEDIATRIC DERMATOLOGY

THE PLACE OF IMMUNOSUPPRESSIVE THERAPY WITH METHOTREXATE IN PEDIATRIC DERMATOLOGY

Mun A.V. - Tashkent State Medical University

Mannanov A.M. - Tashkent State Medical University

Resume

Methotrexate remains one of the key systemic immunomodulatory agents in pediatric dermatology. It is widely used off-label for severe inflammatory dermatoses, including scleroderma, psoriasis, atopic dermatitis, and alopecia areata. Modern understanding of methotrexate’s mechanism of action goes far beyond its classical antifolate effect and includes modulation of purine metabolism with an increase in adenosine levels, influence on JAK/STAT signaling, suppression of T-lymphocyte activation, and antifibrotic activity. This review summarizes fundamental and clinical data describing the molecular mechanisms of methotrexate and their clinical relevance in pediatric dermatology.

Keywords: methotrexate, children, psoriasis, inflammatory dermatoses.

First page

335

Last page

339

For citation:Mun A.V., Mannanov A.M. - THE PLACE OF IMMUNOSUPPRESSIVE THERAPY WITH METHOTREXATE IN PEDIATRIC DERMATOLOGY//New Day in Medicine 12(86)2025 335-339 https://newdayworldmedicine.com/en/new_day_medicine/12-86-2025

List of References

  1. Anderson K, Putterman E, Rogers RS, Patel D, Treat JR, Castelo-Soccio L. Treatment of severe pediatric atopic dermatitis with methotrexate: a retrospective review. Pediatr Dermatol. 2019;36(3):298-302. doi:10.1111/pde.13781
  2. Bronckers IMGJ, Paller AS, West DP, et al. A comparison of psoriasis severity in pediatric patients treated with methotrexate vs biologic agents. JAMA Dermatol. 2020;156(4):384-392. doi:10.1001/ jamadermatol.2019.4835
  3. Deo M, Yung A, Hill S, Rademaker M. Methotrexate for treatment of atopic dermatitis in children and adolescents. Int J Dermatol. 2014; 53(8):1037-1041. doi:10.1111/ijd.12314
  4. D'Souza LS, Payette MJ. Estimated cost efficacy of systemic treatments that are approved by the US Food and Drug Administration for the treatment of moderate to severe psoriasis. J Am Acad Dermatol. 2015;72(4):589-598. doi:10.1016/j.jaad.2014.11.028
  5. Dvorakova V, O'Regan GM, Irvine AD. Methotrexate for severe childhood atopic dermatitis: clinical experience in a tertiary center. Pediatr Dermatol. 2017;34(5):528-534. doi:10.1111/pde.13209
  6. El-Khalawany MA, Hassan H, Shaaban D, Ghonaim N, Eassa B. Methotrexate versus cyclosporine in the treatment of severe atopic dermatitis in children: a multicenter experience from Egypt. Eur J Pediatr. 2013;172(3):351-356. doi:10.1007/s00431-012-1893-3
  7. Ergun T, Seckin Gencosmanoglu D, Alpsoy E, et al. Efficacy, safety and drug survival of conventional agents in pediatric psoriasis: a multicenter, cohort study. J Dermatol. 2017;44(6):630-634. doi:10.1111/1346-8138.13713
  8. Hannoodee M, Mittal M. Methotrexate. StatPearls [Internet]. Stat-Pearls Publishing; 2022.4. Bedoui Y, Guillot X, Sélambarom J, et al. Methotrexate an old drug with new tricks. Int J Mol Sci. 2019;20(20):E5023. doi:10.3390/ijms20205023
  9. Hardy J, Boralevi F, Mallet S, et al. Clinical profile of methotrexate-resistant juvenile localised scleroderma. Acta Derm Venereol. 2019;99(6):539-543. doi:10.2340/00015555-3155
  10. Kaur I, Dogra S, De D, Kanwar AJ. Systemic methotrexate treatment in childhood psoriasis: further experience in 24 children from India. Pediatr Dermatol. 2008;25(2):184-188. doi:10.1111/j.1525-1470. 2008.00629.x

    file

    download